Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Ustekinumab Formulations
NCT02156375Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ustekinumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration and Area under the serum concentration versus time curve from time zero to infinity. Started May 2014; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02156375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156375.